Seeking Alpha

Anonymous 2

Anonymous 2
Send Message
View as an RSS Feed
View Anonymous 2's Comments BY TICKER:
Latest comments  |  Highest rated
  • Cytokinetics' (CYTK) CEO Robert Blum on Q2 2015 Results - Earnings Call Transcript [View article]
    Other than BCLI, CUR and MNOV,which other Biotech companies have a similar R&D research effort to develop a treatment of ALS and or to develop a means to eradicate the disease from occurring in the first place?
    Jul 30, 2015. 09:08 AM | Likes Like |Link to Comment
  • Healthcare ratings roundup [View news story]
    Last I heard, Wedbush still has a TP of $41 on RGLS - That would be nice !!
    maybe asleep at the switch? What is the Biotech analyst's name?
    Jul 23, 2015. 02:12 PM | 1 Like Like |Link to Comment
  • Synthetic Bio prices equity offering [View news story]
    Stockfan1 - Like most relatively small offerings, it was undoubtably sold to key institutional and influential investors with a well known interest in and understanding of such early stage venture like needs for investors who might be able to be accounted on for future and continued financial support.
    My guess as a retired stock broker is that it was sold within a few hours during a few conference calls including a few meetings in NYC and Boston and maybe San Francisco/ Silicon Valley known as centers of Biotech companies.
    Jul 17, 2015. 10:43 AM | Likes Like |Link to Comment
  • Synthetic Biologics plans stock offering; shares -11.6% [View news story]
    My 2 bits - I am long (as low as 1.47 and as high as 2.47 (3/15/15))

    Here Is Why I'm Buying Synthetic Biologics Tue, Jul 7 (dated a week ago)

    This SA article (ABOVE) was only a week ago AT A PRICE BELOW $3/SH-

    Yesterday (Wednesday) SYN ANNOUNCED AN EQUITY OFFERING AT AN UNKNOWN # OF SHARES AND UNKNOWN PRICE.
    IT CLOSED WED AT $3.76 AND IN AFTER MARKET TRADING WAS AS LOW AS 3.29.
    THIS IS 25% LOWER !!! THAN (ONLY !!) YESTERDAY'S RECOVER INTRADAY AND FIVE YEAR HIGH OF $4.32/SH !!!
    Based on the timing of this equity offering - this week or in week or a month in the future?
    and what with Tuesday's RSI indicator at 74 (overbought) and
    BASED ON TECHNICALS ONLY -
    MY GUESS IS THAT THE UNDERWRITERS SHOULD ATTEMPT TO PRICE THE OFFERING AT BEWEEN 3 - 3.25
    BUT IN ANY EVENT ABOVE THE 50 DMAL AND THE 12 MO AGO PEAK OF 2.75
    With a current high 12 month Price target of 12/sh
    (of only 4 analysts - before TAKING INTO AC the DILUTION new equity offering)
    I'll probably add to what is currently 8% of my (7th) largest Bio equity position.

    Other bio's include (largest first)

    BIND (12%) CERU CYTK UNIS CRIS BCLI SYN(8) RXII CUR RGLS MNOV(3%)
    Jul 16, 2015. 03:12 AM | Likes Like |Link to Comment
  • Cytokinetics commences late-stage study of tirasemtiv in ALS [View news story]
    2015 - Year to date - stock performance between 4 companies with an ALS R&D focus.
    MNOV (+ 26%)
    CYTK (-11%)
    BCLI (- 16%)
    CUR (-31%)
    Any other Biotchs missing (above) with such a focus?
    Jul 14, 2015. 10:18 AM | 1 Like Like |Link to Comment
  • Regulus Therapeutics' (RGLS) CEO Kleanthis Xanthopoulos on Q1 2015 Results -- Earnings Call Transcript [View article]
    To what extent (what percent of the potential total global Hep C commercial market) does the company feel that RG-101 could be a direct ? or supplemental
    opportunity for RGLS?
    To what extent would RG-101 be a substitute for the Giliad products? and what is the status or the expected timing of the various testings and if successful,the approval process and timing to move toward human testings as a biomarker "breakthrough"?
    Relative to the current availability of treatments from "competition" - what is the potential timing and process of human testing phase and approval phase before it can be made avaialable to the globalmakets.
    Is this a matter of months or years?
    May 20, 2015. 07:26 PM | Likes Like |Link to Comment
  • A Look At BrainStorm Cell Therapeutics' ALS Phase IIa Results [View article]
    WST: Great article - I have read it and the reader's informed coments and questions and your responses a few times.
    During the past 8 months, I have looked at a few which might be considered BIO Phara companies with some focus on the R&D efforts to find a solution for ALS and or some of the symptoms of ALS patients - such as the following ATHX, BCLI, CUR, CYTK, MNOV, STEM, and a few more undoubtably.
    Now that BCLI has settled down from it's spike (all short covering - or were there new investors with new dollars - net after the first few weeks) in early Jaunary, It would be nice to learn the "percent" of R&D expenses are focused on ALS solutions for ach of these companies. Are "we" forgetting about some of the BIG cap BIO R&D comnpanies who may also be focused on ALS solutions but for which their time and effort and dolars are not much relative to their other (non ALS related)
    projects?
    May 15, 2015. 12:55 PM | Likes Like |Link to Comment
  • NeoStem: The Levi Strauss Of Cell Therapy [View article]
    Time for an update? The current 12 month high target price is still 7.
    May 8, 2015. 10:20 AM | Likes Like |Link to Comment
  • Cytokinetics To Move Tirasemtiv Into Phase III, As FDA Breathes New Life Into ALS Drug [View article]
    Other than BCLI, CUR and CYTK, are there any other SMIDcap ALS R&D focused clinical stage companies which are doing interesting things and should be comparable in various ways to these three?
    Apr 30, 2015. 08:20 PM | Likes Like |Link to Comment
  • Our 2 Healthcare Picks For April [View article]
    In addition to BCLI, CTYK, CTYX, STEM and CUR I recently heard that SYN was involved with R&D research on ALS in their pipeline.Is this true? Are their other companies with an R&D effort toward ALS solutions besides the above?
    I have been long SYN but was unaware of this purported interest in ALS.
    Apr 14, 2015. 09:39 AM | Likes Like |Link to Comment
  • Brainstorm Takes Major Leap Forward In Battle Vs. ALS [View article]
    Since your article first appeared four months ago, have there been any new BioPharma Companies - other than CUR, BCLI, SNY, CYTK, CYTX, STEM which have recently come out as competitive leaders in the search for ALS solutions?
    In order of potential timing in breakthroughs in each of their piplines, which are the two or three "leading horses" to ride during this next 12 to 24 lap.?
    Best sell side FIRMS AND OR analysts who cover ALS R&D research efforts?
    Apr 14, 2015. 03:49 AM | Likes Like |Link to Comment
  • Healthcare stock screen of the month: Price extended, poor fundamentals [View news story]
    CYTX- leaving a bunch of gaps - how many will be filled before next year? next few months?
    Apr 8, 2015. 01:15 PM | 2 Likes Like |Link to Comment
  • It's Time To Invest In BIND Therapeutics [View article]
    Still long MEIP ?
    Do you follow any of the BIOs which have a focus on R&D for ALS syndrome?
    such as BCLI, CUR, CYTK or STEM?
    I own initial positions in the first three (biggest is with BCLI) and am impressed with the recent management and insider investment news from STEM so will probably take a piece of it to incentivize me to get serious to know if and when they deserve some of my retirement dollars.
    Apr 2, 2015. 10:01 PM | Likes Like |Link to Comment
  • Why I'm Short Synthetic Biologics After Phase II Relapsing-Remitting MS Data [View article]
    DO YOU STILL FOLLOW SYN?
    Mar 10, 2015. 02:22 PM | Likes Like |Link to Comment
  • Why I'm Short Synthetic Biologics After Phase II Relapsing-Remitting MS Data [View article]
    Still Short? Seriously - in the past year did SYN pass or correct enough of their flaws to cover and go long?
    How about Keith's RXII. Is this still (and now) a timely turnaround?
    Mar 2, 2015. 10:20 AM | Likes Like |Link to Comment
COMMENTS STATS
367 Comments
133 Likes